Literature DB >> 35849272

Novel approaches to bone comorbidity in Cushing's disease: an update.

Stefano Frara1, Luigi di Filippo1, Mauro Doga1, Paola Loli1, Felipe F Casanueva2, Andrea Giustina3.   

Abstract

Skeletal complications are frequent and clinically relevant findings in Cushing's disease (CD) since an uncoupled suppressed bone formation and enhanced bone resorption leads to a marked skeletal damage with a rapid increase of fracture risk. Reduced Bone Mineral Density (BMD) has been consistently reported and osteopenia or osteoporosis are typical findings in patients with CD. Vertebral Fractures (VFs) are frequently reported and may occur even in patients with an only mild reduction of BMD, representing nowadays a still under- or misdiagnosed comorbidity of these patients being frequently asymptomatic. A novel approach combining different available tools such as BMD evaluation and vertebral morphometry, in order to improve diagnosis, management, and follow-up of bone comorbidity in all patients affected by CD, is needed. This approach is foreseen to be a crucial part of management of patients with CD, particularly in Pituitary Tumor Center of Excellence since VFs, the landmark of the bone involvement, may occur early in the history of the disease and may represent a relevant risk factor for further fractures, reduced quality of life and survival and need for pharmacologic prevention and treatment.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bone mineral density; Cushing’s disease; Glucocorticoids; Osteoporosis; Vertebral fractures; Vertebral morphometry

Year:  2022        PMID: 35849272     DOI: 10.1007/s11102-022-01252-w

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   3.599


  42 in total

Review 1.  Glucocorticoid-induced osteoporosis.

Authors:  F Manelli; A Giustina
Journal:  Trends Endocrinol Metab       Date:  2000-04       Impact factor: 12.015

Review 2.  Perspectives on glucocorticoid-induced osteoporosis.

Authors:  Ernesto Canalis; John P Bilezikian; Alberto Angeli; Andrea Giustina
Journal:  Bone       Date:  2004-04       Impact factor: 4.398

3.  Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006.

Authors:  Amy L Skversky; Juhi Kumar; Matthew K Abramowitz; Frederick J Kaskel; Michal L Melamed
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

Review 4.  Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.

Authors:  Pojchong Chotiyarnwong; Eugene V McCloskey
Journal:  Nat Rev Endocrinol       Date:  2020-04-14       Impact factor: 43.330

5.  Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.

Authors:  Gherardo Mazziotti; Anna Maria Formenti; Robert A Adler; John P Bilezikian; Ashley Grossman; Emilia Sbardella; Salvatore Minisola; Andrea Giustina
Journal:  Endocrine       Date:  2016-10-20       Impact factor: 3.633

Review 6.  Osteopathy in mild adrenal Cushing's syndrome and Cushing disease.

Authors:  Stefano Frara; Agnese Allora; Luigi di Filippo; Anna Maria Formenti; Paola Loli; Elisabetta Polizzi; Daniele Tradati; Fabio Massimo Ulivieri; Andrea Giustina
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2021-03-10       Impact factor: 4.690

Review 7.  Consensus on diagnosis and management of Cushing's disease: a guideline update.

Authors:  Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-20       Impact factor: 32.069

8.  High Prevalence of Vertebral Fractures Associated With Preoperative GH Levels in Patients With Recent Diagnosis of Acromegaly.

Authors:  Stefano Frara; Meliha Melin Uygur; Luigi di Filippo; Mauro Doga; Marco Losa; Simona Santoro; Pietro Mortini; Andrea Giustina
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

Review 9.  Glucocorticoids and the regulation of growth hormone secretion.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

Review 10.  Glucocorticoid-induced osteoporosis: pathophysiology and therapy.

Authors:  E Canalis; G Mazziotti; A Giustina; J P Bilezikian
Journal:  Osteoporos Int       Date:  2007-06-14       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.